AbbVie Beats Earnings as Skyrizi and Rinvoq Offset Humira Decline
AbbVie reported quarterly earnings that exceeded expectations, driven by strong sales of newer drugs Skyrizi and Rinvoq, which together generated over $6.6 billion. This performance offset the continued decline of Humira, which brought in $688 million. The company also raised its full-year outlook, signaling confidence in its pipeline. The results highlight AbbVie's successful transition away from reliance on Humira, once the world's top-selling drug.
Key facts
- AbbVie beat earnings expectations.
- Skyrizi and Rinvoq generated over $6.6 billion in quarterly sales.
- Humira sales were $688 million.
- AbbVie raised its full-year outlook.
- Newer drugs offset Humira's decline.
Entities
Institutions
- AbbVie
Sources
- Quartz —